|
|
Volumn 471, Issue 7336, 2011, Pages 16-
|
|
Targeted gene editing enters clinic
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CHEMOKINE RECEPTOR CCR5;
NUCLEASE;
UNCLASSIFIED DRUG;
ZINC FINGER NUCLEASE;
ZINC FINGER PROTEIN;
ABSENCE OF SIDE EFFECTS;
CD4+ T LYMPHOCYTE;
EXPERIMENTAL THERAPY;
GENE TARGETING;
GENE THERAPY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
NOTE;
PRIORITY JOURNAL;
RECEPTOR GENE;
RNA EDITING;
TREATMENT OUTCOME;
CD4-POSITIVE T-LYMPHOCYTES;
CLINICAL TRIALS, PHASE I AS TOPIC;
ENDODEOXYRIBONUCLEASES;
GENE KNOCKOUT TECHNIQUES;
HIV INFECTIONS;
HUMANS;
RECEPTORS, CCR5;
ZINC FINGERS;
|
|
EID: 79952262602
PISSN: 00280836
EISSN: 14764687
Source Type: Journal
DOI: 10.1038/471016a Document Type: Note |
|
Times cited : (12)
|
|
References (0)
|
